FY2027 EPS Estimates for Pfizer Cut by Leerink Partnrs

Key Points

• Leerink Partners has revised its FY2027 earnings per share estimate for Pfizer down to $3.21, slightly lower than the previous estimate of $3.24.
• Pfizer's stock has performed relatively stable, trading at $24.38 with a market cap of $138.58 billion and a current ratio of 1.16.
• Recent institutional trading indicates strong investor interest, with 68.36% of the company's stock held by institutional investors and hedge funds.

Pfizer Inc. (NYSE:PFE - Free Report) - Investment analysts at Leerink Partnrs lowered their FY2027 earnings per share (EPS) estimates for Pfizer in a note issued to investors on Tuesday, August 5th. Leerink Partnrs analyst D. Risinger now expects that the biopharmaceutical company will post earnings of $3.21 per share for the year, down from their previous estimate of $3.24. The consensus estimate for Pfizer's current full-year earnings is $2.95 per share.

Several other research firms have also recently issued reports on PFE. Redburn Atlantic cut their target price on Pfizer from $29.00 to $27.00 and set a "neutral" rating for the company in a research report on Wednesday, April 30th. TD Cowen lowered their price objective on Pfizer from $32.00 to $28.00 and set a "hold" rating for the company in a research note on Tuesday, April 22nd. The Goldman Sachs Group raised their price objective on Pfizer from $25.00 to $27.00 and gave the company a "neutral" rating in a research note on Wednesday, April 30th. Wolfe Research raised their price target on Pfizer from $22.00 to $23.00 and gave the stock an "underperform" rating in a research note on Wednesday, April 30th. Finally, Leerink Partners reduced their price objective on Pfizer from $28.00 to $26.00 and set a "market perform" rating on the stock in a report on Wednesday, April 30th. One investment analyst has rated the stock with a sell rating, eleven have given a hold rating, five have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of "Hold" and an average price target of $28.12.

Pfizer Stock Performance

PFE stock traded up $0.15 during trading on Friday, reaching $24.38. The stock had a trading volume of 11,670,230 shares, compared to its average volume of 45,834,473. Pfizer has a 52 week low of $20.92 and a 52 week high of $30.43. The stock's 50 day moving average is $24.42 and its two-hundred day moving average is $24.52. The company has a current ratio of 1.16, a quick ratio of 0.96 and a debt-to-equity ratio of 0.65. The firm has a market cap of $138.58 billion, a PE ratio of 12.98, a PEG ratio of 0.87 and a beta of 0.52.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.58 by $0.20. The firm had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%. The company's quarterly revenue was up 10.3% on a year-over-year basis. During the same period in the prior year, the company posted $0.60 earnings per share.

Institutional Trading of Pfizer

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Capital Advisory Group Advisory Services LLC lifted its position in Pfizer by 2.9% during the 2nd quarter. Capital Advisory Group Advisory Services LLC now owns 13,542 shares of the biopharmaceutical company's stock worth $328,000 after acquiring an additional 388 shares during the period. Citizens National Bank Trust Department increased its stake in shares of Pfizer by 0.9% in the 2nd quarter. Citizens National Bank Trust Department now owns 46,103 shares of the biopharmaceutical company's stock valued at $1,118,000 after purchasing an additional 395 shares in the last quarter. Able Wealth Management LLC increased its stake in shares of Pfizer by 2.0% in the 2nd quarter. Able Wealth Management LLC now owns 21,128 shares of the biopharmaceutical company's stock valued at $512,000 after purchasing an additional 413 shares in the last quarter. Trust Co of the South raised its holdings in shares of Pfizer by 1.5% during the second quarter. Trust Co of the South now owns 29,386 shares of the biopharmaceutical company's stock valued at $712,000 after acquiring an additional 441 shares during the last quarter. Finally, Charter Oak Capital Management LLC raised its holdings in shares of Pfizer by 4.3% during the second quarter. Charter Oak Capital Management LLC now owns 10,663 shares of the biopharmaceutical company's stock valued at $258,000 after acquiring an additional 444 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company's stock.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a yield of 7.1%. Pfizer's payout ratio is currently 91.49%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.